Vaxxas, Inc. news

Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines.

The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a possible alternative to traditional vaccine delivery methods which haven’t seen new techn